|Dr. R. Scott Struthers||Founder, Pres, CEO & Director||783.8k||N/A||1962|
|Mr. Marc J. C. Wilson||CFO & Sec.||418.74k||N/A||1979|
|Dr. Alan S. Krasner||Chief Medical Officer||491.43k||N/A||1963|
|Dr. Stephen F. Betz||Co-Founder & VP of Biology||N/A||N/A||1966|
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.